Epunamin plus DECP for returning or resistant multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of the study drug Epunamin with four chemotherapy drugs (dexamethasone, cisplatin, etoposide, and cyclophosphamide) for people whose multiple myeloma has come back or stopped responding to earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and have multiple myeloma that has returned or is resistant to treatment.
- You have already received at least one prior treatment for your myeloma.
- Your major organs (heart, lungs, liver, kidneys) are working well enough, with no severe problems.
- You are not pregnant or breastfeeding and are willing to use effective birth control during the study.
- You do not have another active cancer in the last 2 years or a serious infection needing antibiotics within the past 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
This trial tests different dosing schedules of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) together to treat multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find a dosing plan that works well and is tolerable for patients.
This trial studies a new medicine called elranatamab combined with the chemotherapy drug cyclophosphamide for people with multiple myeloma that has returned or not responded to prior treatments. It may be a good option if you have aggressive or high-risk myeloma.
This trial tests whether combining radiation therapy with the drug elranatamab can help people with multiple myeloma that has come back or not responded to treatment, especially when the cancer has spread to soft tissues or bones outside the bone marrow. The goal is to see if this combination can make the immune system fight the cancer more effectively.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.